Special Issue "Microbial Antigen Delivery"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 31 July 2018

Special Issue Editor

Guest Editor
Prof. Dr. Shiladitya DasSarma

Department of Microbiology and Immunology, University of Maryland School of Medicine; Institute of Marine and Environmental Technology, University System of Maryland, Columbus Center, 701 E. Pratt St., Baltimore, MD 21202 USA
Website | E-Mail
Interests: expression systems; antigen delivery; malaria; typhoid; sepsis; cancer; halophiles; Archaea

Special Issue Information

Dear Colleagues,

Many strategies are currently being developed to expand the repertoire of preventative and therapeutic vaccines against a variety of diseases. Diverse microbial systems are being utilized, from Archaea to Bacteria, Fungi, and Viruses, which offer advantages over traditional vaccines. Notable among them are recombinant vectors, liposomes and nanoparticles, and other customizable delivery vehicles that are designed to increase immunogenicity and efficacy, while reducing toxicity and adverse effects. Compared to live-attenuated, inactivated or killed pathogens, microbial antigen delivery systems may offer greater safety, increased stability, optimized presentation, enhanced adjuvant effect, and improved immunogenicity, potentially reducing the immunization and dosage requirements. They hold the promise of eliciting a full adaptive immune response as well as long-term systemic humoral and cell-mediated immunity. As a result, microbial antigen delivery systems may help cure some of the most widespread and pervasive as well as rare and orphaned diseases. Of particular importance in the 21st century are emerging and re-emerging infectious diseases, long-standing tropical infectious diseases, and hematological malignancies and solid tumors. This special issue of Vaccines will cover topics relevant to new and developing systems for microbial antigen delivery.

Prof. Dr. Shiladitya DasSarma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • expression systems
  • customizable delivery vehicles
  • adjuvant effects
  • immunogenicity
  • therapeutic vaccines
  • cancer vaccines

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Newcastle Disease Virus Vectored Bivalent Vaccine against Virulent Infectious Bursal Disease and Newcastle Disease of Chickens
Received: 14 August 2017 / Revised: 13 September 2017 / Accepted: 22 September 2017 / Published: 26 September 2017
Cited by 1 | PDF Full-text (2898 KB) | HTML Full-text | XML Full-text
Abstract
Newcastle disease virus (NDV) strain F is a lentogenic vaccine strain used for primary vaccination in day-old chickens against Newcastle disease (ND) in India and Southeast Asian countries. Recombinant NDV-F virus and another recombinant NDV harboring the major capsid protein VP2 gene of
[...] Read more.
Newcastle disease virus (NDV) strain F is a lentogenic vaccine strain used for primary vaccination in day-old chickens against Newcastle disease (ND) in India and Southeast Asian countries. Recombinant NDV-F virus and another recombinant NDV harboring the major capsid protein VP2 gene of a very virulent infectious bursal disease virus (IBDV); namely rNDV-F and rNDV-F/VP2, respectively, were generated using the NDV F strain. The rNDV-F/VP2 virus was slightly attenuated, as compared to the rNDV-F virus, as evidenced from the mean death time and intracerebral pathogenicity index analysis. This result indicates that rNDV-F/VP2 behaves as a lentogenic virus and it is stable even after 10 serial passages in embryonated chicken eggs. When chickens were vaccinated with the rNDV F/VP2, it induced both humoral and cell mediated immunity, and was able to confer complete protection against very virulent IBDV challenge and 80% protection against virulent NDV challenge. These results suggest that rNDV-F could be an effective and inherently safe vaccine vector. Here, we demonstrate that a bivalent NDV-IBDV vaccine candidate generated by reverse genetics method is safe, efficacious and cost-effective, which will greatly aid the poultry industry in developing countries. Full article
(This article belongs to the Special Issue Microbial Antigen Delivery)
Figures

Figure 1

Back to Top